Omeprazole vs. Famotidine – Quick Reference
| Feature | Omeprazole (Proton‑Pump Inhibitor, PPI) | Famotidine (H2‑Receptor Antagonist, H2RA) |
|---------|------------------------------------------|-------------------------------------------|
| Drug class | Proton‑pump inhibitor (PPI) | H2‑receptor antagonist (H2RA) |
| Mechanism of action | Blocks the H⁺/K⁺‑ATPase (“proton pump”) in parietal cells → irreversible inhibition of gastric acid secretion. | Antagonizes H₂ receptors on parietal cells → competitive inhibition → decreased acid secretion. |
| Onset of action | 1–2 hours, but maximal effect after 4–6 days of continuous dosing. | 30–60 minutes, peak effect in 1–3 hours. |
| Duration of action | 24 hours (effect persists for ~24 h due to irreversible pump inhibition). | 4–6 hours (shorter duration). |
| Typical uses | • Gastro‑oesophageal reflux disease (GERD) < 8 weeks
• Erosive esophagitis
• Peptic ulcer disease (especially H. pylori eradication regimens)
• Zollinger–Ellison syndrome
• Prevention of NSAID‑induced ulcers | • Mild‑to‑moderate GERD
• Non‑erosive reflux disease
• Post‑reflux heartburn
• Helicobacter‑associated ulcer when used as maintenance
• Acute peptic ulcer bleeding (short‑term) |
| Typical doses | 20 mg or 40 mg PO once daily (often 24 h prior to first meal). | 20 mg PO twice daily or 40 mg once daily (may be taken up to 3 h before meals). |
| Common side effects | • Headache
• Nausea, diarrhea, flatulence
• Abdominal pain
• Rare: interstitial nephritis, Clostridioides difficile colitis, low magnesium, rebound acid hypersecretion (if abruptly stopped) | • Headache
• Diarrhea
• Constipation
• Dizziness
• Rare: rash, thrombocytopenia |
| Drug interactions | • CYP2C19 inhibitors/inducers (clopidogrel, proton pump inhibitors, etc.)
• Requires CYP2C19 inhibition for clopidogrel efficacy
• May increase risk of C. difficile infection
• May interact with drugs that require acidic pH for absorption (e.g., ketoconazole) | • Metabolized via CYP1A2, CYP2D6 (less extensive than PPIs)
• Can alter absorption of drugs requiring acidic pH (e.g., ketoconazole, some antifungals)
• May increase clopidogrel activation (less clinically significant) |
| Special considerations | • Long‑term use associated with vitamin B12 deficiency, osteoporosis, hypomagnesemia, increased risk of fractures, infections (C. difficile, pneumonia).
• Rebound acid hypersecretion if stopped abruptly. | • Shorter term use; less impact on micronutrients.
• Less risk of rebound acid secretion. |
| Cost & availability | Generic widely available; usually slightly more expensive than H2RAs but still affordable. | Generic, often cheaper, especially for 20 mg tablets. |
| Patient‑specific factors | • Patients needing strong acid suppression (e.g., erosive esophagitis, ulcers, high‑risk NSAID users).
• Patients with H. pylori infection requiring combination therapy. | • Patients with mild heartburn or non‑erosive disease.
• Patients who are cost‑sensitive or need a shorter course. |
---
Key Take‑Home Points
1. Potency & Duration – Omeprazole produces a more profound, longer‑lasting acid suppression than famotidine. That’s why PPIs are first‑line for erosive esophagitis or peptic ulcer disease, while H2RAs are usually reserved for milder or short‑term issues.
2. Onset & Use‑Timing – Famotidine works faster (30–60 min) and can be taken just before meals. Omeprazole takes a few hours to reach peak effect and is best taken before the first meal of the day.
3. Side‑Effect Profile – Both are generally safe, but long‑term PPI use carries additional risks (vitamin B12, magnesium, bone health, infections). H2RA use is associated with fewer systemic side effects.
4. Drug‑Drug Interactions – Omeprazole interferes more with other drugs (especially those metabolized by CYP2C19) and can affect clopidogrel efficacy. Famotidine’s interaction profile is milder but still warrants attention for drugs that need an acidic environment for absorption.
5. Cost & Accessibility – Famotidine is usually cheaper and can be a good first‑line for uncomplicated heartburn. For patients who need more robust acid control or are at higher risk of complications (ulcers, NSAID use, GERD with erosive lesions), omeprazole is often preferred despite the higher cost.
---
When to Ask a Doctor
- Long‑term use: Discuss monitoring of magnesium, vitamin B12, and bone density.
- Switching: Abruptly stopping omeprazole can cause rebound acid hypersecretion—plan a taper if necessary.
- Contraindications: Allergies, liver disease, or drug‑specific interactions should be reviewed.
- Special populations: Pregnancy, lactation, pediatric use – consult prescribing info or a pharmacist.
---
Bottom line:
- Omeprazole = stronger, longer‑acting acid suppression, ideal for ulcers, erosive GERD, and high‑risk patients.
- Famotidine = milder, quicker onset, suitable for mild heartburn, non‑erosive reflux, or short‑term relief.
Both are effective; the choice depends on the severity of symptoms, underlying conditions, duration of therapy, patient cost considerations, and potential drug interactions. If you’re unsure which to take, let your prescriber tailor the therapy to your specific situation.